ValiRx Regulatory News (VAL)

ValiRx Plc

("ValiRx" or "the Company")

ValiSeek Clinical Development Update

London, UK., 01 December 2016: ValiRx Plc (AIM: VAL), a life science company, which focuses on clinical stage cancer therapeutic development, taking proprietary & novel technology for precision medicines towards commercialisation and partnering, is pleased to provide a development update on the clinical development of ValiSeek, the joint venture between ValiRx and Tangent Reprofiling Limited.

ValiSeek was formed to progress the novel cancer treatment drug, VAL401, into Clinical Efficacy trials for the treatment of lung cancer and other oncology indications.

Further to our announcement on 3 November 2016 regarding the successful dosing of the first patient with VAL401, ValiSeek is pleased to confirm the initiation of the process to commission a second clinical testing site under our protocol VAL401-001 "A Phase II study to assess the efficacy, safety and tolerability of VAL401 in the treatment of patients with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) after failure of at least one prior chemotherapeutic regimen".

As part of this process, the protocol and supporting documentation have been reviewed by the ethics committee at the second Tbilisi site, the JSC Neo Medi Clinic, and they have now returned a positive opinion and approval.

This opinion will now be submitted to the Georgian Competent Authority for the regulation of trials, the Ministry of Labour, Health and Social Affairs of Georgia. This regulatory step will allow the set-up of the new clinical trial site and enable the clinical team to begin identifying further patients for recruitment into the trial.

Dr Suzanne Dilly, CEO of ValiSeek Limited, commented: "We're delighted that the formal process for initiating our new site has successfully launched. After visiting Neo Medi during our trip earlier this month, we are keen to get the team fully operational early in New Year."

Dr George Morris, COO of ValiRx Plc, added: "This trial expansion to include a second site is a strong endorsement of the results currently being acquired and we are delighted that ValiSeek continues to see such good progress."

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

*** ENDS ***

For more information, please contact:

Notes for Editors

About ValiSeek

ValiSeek Limited ("ValiSeek") is a joint venture ("JV") company between ValiRx Plc and Tangent Reprofiling Limited, part of the SEEK Group. ValiSeek was formed to progress the drug VAL401 through its remaining preclinical development and towards Phase II trials for the treatment of lung cancer and other oncology indications

About SEEK

Founded in 2004, SEEK (previously known as PepTcell) is privately-owned and funded, with headquarters in London, UK. SEEK brings safe and low costs medicines to the patients as quickly as possible. It does this by modifying existing medicines to improve their efficacy within current label, dose and regime, by changing the indication but keeping the dose and dosing regime the same or by creating a new medicine when the previous options are unavailable.

Additional information about SEEK is available on the Company's website located at www.seekacure.com.

ValiRx Plc

ValiRx is a biotechnology oncology focussed company specialising in developing novel treatments for cancer and associated biomarkers. It aims to make a significant contribution in "precision" medicine and science, namely to engineer a breakthrough into human health and well-being, through the early detection of cancer and its therapeutic intervention.

The Company's business model focuses on out-licensing therapeutic candidates early in the development process. By aiming for early-stage value creation, the company reduces risk considerably while increasing the potential for realising value. The group is already in licensing discussions with major players in the oncology field.

ValiRx's two classes of drugs in development, which each have the potential for meeting hitherto unmet medical needs by existing methods, have worldwide patent filings and agreed commercial rights. They originate or derive from Word class institutions, such as Cancer Research UK and Imperial College.

Until recently, cancer treatments relied on non-specific agents, such as chemotherapy. With the development of target-based agents, primed to attack cancer cells only, less toxic and more effective treatments are now possible. New drugs in this group-such as those in ValiRx's pipeline-promise to greatly improve outcomes for cancer patients.

The Company listed on the Alternative Investment Market ("AIM") of the London Stock Exchange in October 2006 and trades under the ticker symbol: VAL.